Pfizer says phase 3 data buoys Litfulo as a vitiligo treatment

Pfizer (PFE) reported positive Phase 3 trial results for LITFULO, a vitiligo treatment, showing significant skin repigmentation. The company plans regulatory submissions. PFE has a 6.35% dividend yield, a payout ratio of 0.71, and a GF Score of 71/100, indicating fair valuation but modest growth.

Pfizer Inc (PFE) reported positive phase 3 trial results for Litfulo (ritlecitinib) in treating vitiligo, showing significant improvements over placebo. The company has a $156.79B market cap, offers a 6.35% dividend yield, and has a GF Score of 71/100, indicating solid profitability and valuation but modest growth. Insiders and investment gurus show mixed activity. PFE's stock is fairly valued, trading 4.0% above its intrinsic value of $26.45.

Florida sued Pfizer and its CEO, alleging deceptive marketing of the COVID-19 vaccine. The state seeks damages and an injunction, claiming Pfizer misled consumers. Pfizer denies wrongdoing, stating its claims were accurate and science-based. A 2025 grand jury found no evidence of lawbreaking by vaccine manufacturers.

Florida sued Pfizer and CEO Albert Bourla, alleging deceptive practices regarding COVID-19 vaccine safety, efficacy, and marketing. The lawsuit claims Pfizer misled consumers about risks like myocarditis and pregnancy complications, and overstated the vaccine's ability to prevent transmission. Florida seeks damages under state consumer-protection laws, while Pfizer denies wrongdoing and calls the case meritless.

Pfizer's LITFULO (ritlecitinib) significantly improved facial and total body repigmentation in Phase 3 trials for nonsegmental vitiligo, with 21.86% and 12.47% of patients achieving F-VASI75 compared to placebo. The company plans regulatory filings, including with the FDA and EMA. Safety data was consistent with its known profile. According to Pfizer, LITFULO addresses the root cause of the disease. (PFE)

Pfizer (PFE) faced a lawsuit from Florida over COVID-19 vaccine claims while reporting positive Phase 2 data for its eczema drug, tilrekimig. Shares fell 1.40% to $28.12. The company expects COVID-19 revenue to decline to $4 billion by 2026. Analysts have raised 2026 revenue estimates but lowered long-term forecasts.